Madrigal Pharmaceuticals: Peers

The FY2025 (Dec) proxy of Madrigal Pharmaceuticals names 16 peer companies for pay. Among Madrigal Pharmaceuticals and these peers, CEO pay was 3rd highest of 11 and total shareholder return was the highest of 11.

3rd highest of 11in Madrigal Pharmaceuticals and its pay peers, FY2025 (Dec) by CEO pay:

$6.9M$33.2M

1st highest of 11in Madrigal Pharmaceuticals and its pay peers, FY2025 (Dec) by total shareholder return:

$17$524

Pay peer group, FY2025 (Dec) proxy

Exelixis
Halozyme Therapeutics
BridgeBio Pharma
Alnylam Pharmaceuticals
INSMED
Ionis Pharmaceuticals
Ultragenyx Pharmaceutical
Krystal Biotech
CRISPR Therapeutics AG
Neurocrine Biosciences
Apellis PharmaceuticalsNot disclosedNot disclosed
Blueprint MedicinesNot disclosedNot disclosed
CytokineticsNot disclosedNot disclosed
Intra-Cellular TherapiesNot disclosedNot disclosed
Roivant SciencesNot disclosedNot disclosed
Sarepta TherapeuticsNot disclosedNot disclosed
16 companies

Changes by year

FY2025 (Dec) proxy

  • RemovedAcadiapay peer groupThe Compensation Committee determined that Acadia, Amicus Therapeutics, Inc., Arrowhead Pharmaceuticals, Inc., Axsome Therapeutics, Inc., Corcept Therapeutics, Incorporated, Denali Therapeutics Inc. and Harmony Biosciences Management, Inc. were no longer appropriate peers based on their low market capitalization relative to our criteria and ImmunoGen, Inc., Mirati Therapeutics, Inc. and Reata Pharmaceuticals, Inc. were acquired and no longer relevant
  • RemovedAmicus Therapeutics, Inc.pay peer groupThe Compensation Committee determined that Acadia, Amicus Therapeutics, Inc., Arrowhead Pharmaceuticals, Inc., Axsome Therapeutics, Inc., Corcept Therapeutics, Incorporated, Denali Therapeutics Inc. and Harmony Biosciences Management, Inc. were no longer appropriate peers based on their low market capitalization relative to our criteria and ImmunoGen, Inc., Mirati Therapeutics, Inc. and Reata Pharmaceuticals, Inc. were acquired and no longer relevant
  • RemovedArrowhead Pharmaceuticals, Inc.pay peer groupThe Compensation Committee determined that Acadia, Amicus Therapeutics, Inc., Arrowhead Pharmaceuticals, Inc., Axsome Therapeutics, Inc., Corcept Therapeutics, Incorporated, Denali Therapeutics Inc. and Harmony Biosciences Management, Inc. were no longer appropriate peers based on their low market capitalization relative to our criteria and ImmunoGen, Inc., Mirati Therapeutics, Inc. and Reata Pharmaceuticals, Inc. were acquired and no longer relevant
  • RemovedAxsome Therapeuticspay peer groupThe Compensation Committee determined that Acadia, Amicus Therapeutics, Inc., Arrowhead Pharmaceuticals, Inc., Axsome Therapeutics, Inc., Corcept Therapeutics, Incorporated, Denali Therapeutics Inc. and Harmony Biosciences Management, Inc. were no longer appropriate peers based on their low market capitalization relative to our criteria and ImmunoGen, Inc., Mirati Therapeutics, Inc. and Reata Pharmaceuticals, Inc. were acquired and no longer relevant
  • RemovedCorcept Therapeuticspay peer groupThe Compensation Committee determined that Acadia, Amicus Therapeutics, Inc., Arrowhead Pharmaceuticals, Inc., Axsome Therapeutics, Inc., Corcept Therapeutics, Incorporated, Denali Therapeutics Inc. and Harmony Biosciences Management, Inc. were no longer appropriate peers based on their low market capitalization relative to our criteria and ImmunoGen, Inc., Mirati Therapeutics, Inc. and Reata Pharmaceuticals, Inc. were acquired and no longer relevant
  • RemovedDenali Therapeutics Inc.pay peer groupThe Compensation Committee determined that Acadia, Amicus Therapeutics, Inc., Arrowhead Pharmaceuticals, Inc., Axsome Therapeutics, Inc., Corcept Therapeutics, Incorporated, Denali Therapeutics Inc. and Harmony Biosciences Management, Inc. were no longer appropriate peers based on their low market capitalization relative to our criteria and ImmunoGen, Inc., Mirati Therapeutics, Inc. and Reata Pharmaceuticals, Inc. were acquired and no longer relevant
  • RemovedHarmony Biosciences Management, Inc.pay peer groupThe Compensation Committee determined that Acadia, Amicus Therapeutics, Inc., Arrowhead Pharmaceuticals, Inc., Axsome Therapeutics, Inc., Corcept Therapeutics, Incorporated, Denali Therapeutics Inc. and Harmony Biosciences Management, Inc. were no longer appropriate peers based on their low market capitalization relative to our criteria and ImmunoGen, Inc., Mirati Therapeutics, Inc. and Reata Pharmaceuticals, Inc. were acquired and no longer relevant
  • RemovedImmunoGen, Inc.pay peer groupThe Compensation Committee determined that Acadia, Amicus Therapeutics, Inc., Arrowhead Pharmaceuticals, Inc., Axsome Therapeutics, Inc., Corcept Therapeutics, Incorporated, Denali Therapeutics Inc. and Harmony Biosciences Management, Inc. were no longer appropriate peers based on their low market capitalization relative to our criteria and ImmunoGen, Inc., Mirati Therapeutics, Inc. and Reata Pharmaceuticals, Inc. were acquired and no longer relevant
  • RemovedMirati Therapeutics, Inc.pay peer groupThe Compensation Committee determined that Acadia, Amicus Therapeutics, Inc., Arrowhead Pharmaceuticals, Inc., Axsome Therapeutics, Inc., Corcept Therapeutics, Incorporated, Denali Therapeutics Inc. and Harmony Biosciences Management, Inc. were no longer appropriate peers based on their low market capitalization relative to our criteria and ImmunoGen, Inc., Mirati Therapeutics, Inc. and Reata Pharmaceuticals, Inc. were acquired and no longer relevant
  • RemovedReata Pharmaceuticals, Inc.pay peer groupThe Compensation Committee determined that Acadia, Amicus Therapeutics, Inc., Arrowhead Pharmaceuticals, Inc., Axsome Therapeutics, Inc., Corcept Therapeutics, Incorporated, Denali Therapeutics Inc. and Harmony Biosciences Management, Inc. were no longer appropriate peers based on their low market capitalization relative to our criteria and ImmunoGen, Inc., Mirati Therapeutics, Inc. and Reata Pharmaceuticals, Inc. were acquired and no longer relevant

FY2024 (Dec) proxy

  • RemovedAgios Pharmaceuticalspay peer groupThe Compensation Committee determined that Agios Pharmaceuticals, Cara Therapeutics, Cytokinetics, FibroGen, Global Blood Therapeutics, IVERIC bio, REGENXBIO and Travere Therapeutics were no longer appropriate peers based on their low market capitalization relative to our criteria
  • RemovedCara Therapeuticspay peer groupThe Compensation Committee determined that Agios Pharmaceuticals, Cara Therapeutics, Cytokinetics, FibroGen, Global Blood Therapeutics, IVERIC bio, REGENXBIO and Travere Therapeutics were no longer appropriate peers based on their low market capitalization relative to our criteria
  • RemovedCytokineticspay peer groupThe Compensation Committee determined that Agios Pharmaceuticals, Cara Therapeutics, Cytokinetics, FibroGen, Global Blood Therapeutics, IVERIC bio, REGENXBIO and Travere Therapeutics were no longer appropriate peers based on their low market capitalization relative to our criteria
  • RemovedFibroGenpay peer groupThe Compensation Committee determined that Agios Pharmaceuticals, Cara Therapeutics, Cytokinetics, FibroGen, Global Blood Therapeutics, IVERIC bio, REGENXBIO and Travere Therapeutics were no longer appropriate peers based on their low market capitalization relative to our criteria
  • RemovedGlobal Blood Therapeuticspay peer groupThe Compensation Committee determined that Agios Pharmaceuticals, Cara Therapeutics, Cytokinetics, FibroGen, Global Blood Therapeutics, IVERIC bio, REGENXBIO and Travere Therapeutics were no longer appropriate peers based on their low market capitalization relative to our criteria
  • RemovedIVERICpay peer groupThe Compensation Committee determined that Agios Pharmaceuticals, Cara Therapeutics, Cytokinetics, FibroGen, Global Blood Therapeutics, IVERIC bio, REGENXBIO and Travere Therapeutics were no longer appropriate peers based on their low market capitalization relative to our criteria
  • RemovedREGENXBIOpay peer groupThe Compensation Committee determined that Agios Pharmaceuticals, Cara Therapeutics, Cytokinetics, FibroGen, Global Blood Therapeutics, IVERIC bio, REGENXBIO and Travere Therapeutics were no longer appropriate peers based on their low market capitalization relative to our criteria
  • RemovedTravere Therapeuticspay peer groupThe Compensation Committee determined that Agios Pharmaceuticals, Cara Therapeutics, Cytokinetics, FibroGen, Global Blood Therapeutics, IVERIC bio, REGENXBIO and Travere Therapeutics were no longer appropriate peers based on their low market capitalization relative to our criteria

FY2023 (Dec) proxy

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.